With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.
(d) 1-(3-(2, 5-dioxo-2 , 5-dihydro- 1H-pyrrol- 1-yl)propanamido)-N-((S)- 1-(((S)- 1-((4-((S)-7- methoxy-8-((5-(((S)- 7-methoxy-2-(4-(4-methylpiperazin- 1-yl)phenyl)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-8-yl) oxy)pentyl) oxy)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-2-yl)phenyl)amino) – 1-oxopropan-2-yl)amino)-3-methyl- 1- oxobutan-2-yl)-3, 6,9, 12,15, 18,21, 24-octaoxaheptacosan-2 7-amide (91)Piperidine (0.2 mL) was added to a solution of 90 (77 mg, 63.4 pmol) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over Mg504, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)8-acid (56 mg, 95 pmol) and EDCI (18 mg, 95 pmol) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS (1.19 mm (ES+) m/z(relative intensity) 784.25 (([M+ 2H]2j/2, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried (MgSO4), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCI3/MeOH to 90:10 v/v CHCI3/MeOH) gave 91 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, ODd3) O 8.73 (5, 1H), 7.88 (dd, J= 7.6, 3.9 Hz, 2H), 7.75 (d, J= 8.6 Hz, 2H), 7.52 (d, J= 2.0 Hz, 2H), 7.44 (5, 1H), 7.40-7.28 (m, 4H), 6.91 (d, J= 8.8 Hz, 2H), 6.81 (5, 2H), 6.69 (5, 2H),6.48 (5, 1 H), 4.72 -4.63 (m, 1 H), 4.46 -4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (5, 4H), 3.84 (dd, J = 17.2, 10.1 Hz, 4H), 3.72 -3.46 (m, 30H), 3.44 -3.32 (m, 4H), 3.30-3.20 (m, 4H), 2.75-2.63 (m, 1H), 2.59 (5, 4H), 2.55-2.43 (m, 3H), 2.37 (5, 3H), 2.29 (dd, J= 12.7, 6.7 Hz, 1H), 2.03-1.89 (m, 4H), 1.72 (d, J= 22.7 Hz, 8H), 1.46 (d, J= 7.2 Hz, 3H), 1.01 (dd, J = 11.5, 6.9 Hz, 6H). MS (ES) m/z (relative intensity) 784.25 (([M+ 2H]2)/2, 100).
1334177-86-4, As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.
Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; VAN BERKEL, Patricius Henrikus Cornelis; HOWARD, Philip Wilson; WILLIAMS, David G; WO2015/159076; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem